NEJM data and RMAT in hand, PM359 races toward a BLA on single-patient proof-of-concept while cash runs to 2027

Prime Medicine is an early-stage gene therapy company developing a treatment for chronic granulomatous disease, a fatal immunodeficiency, that is not yet approved.

PM359, a prime-editing therapy for p47phox chronic granulomatous disease, a fatal immunodeficiency, reached the NEJM with one patient showing 66% NADPH oxidase restoration and rapid engraftment, earning RMAT designation and anchoring a planned H1 2027 BLA. The thesis resolves on whether FDA accepts that single-patient, early-stage dataset as sufficient for accelerated approval, a genuinely novel and unresolved regulatory question for prime editing. Cash of $109M at roughly $20M quarterly burn likely extends only to mid-2027, leaving virtually no buffer if the BLA filing slips or triggers a Complete Response.